AI Article Synopsis
- Arsenic trioxide and all-retinoic acid are now primary treatments for acute promyelocytic leukemia (APL), with the oral arsenic drug realgar-indigo naturalis formula (RIF) becoming available in China in 2009.
- Over 5,000 APL patients in China have since benefited from RIF, which provides similar effectiveness to intravenous treatments but offers better safety, improved quality of life, and reduced medical costs.
- The positive outcomes suggest a shift towards adopting outpatient postremission therapy for both low-risk and high-risk APL patients in clinical settings.
Article Abstract
Arsenic trioxide and all- retinoic acid have become the frontline treatments for patients with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a commercially available agent, realgar-indigo naturalis formula (RIF), was not launched in China until 2009. Since then, over 5000 APL patients have been treated with oral RIF in China. Oral arsenic not only shows a clinical efficacy comparable to that of IV formulations but also displays a better safety profile, improved quality of life, and lower medical costs for patients. The promising results promote incorporating an outpatient postremission therapy model into clinical practice for both low-risk and high-risk APL patients in China. In this review, we discuss the evolution of oral arsenic RIF in the treatment of APL, with a special focus on how to address the related complications during induction therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2019000760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!